E. Ohman J or Asset Management AB Has $1.93 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

E. Ohman J or Asset Management AB lessened its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 26.0% during the 4th quarter, HoldingsChannel reports. The firm owned 34,781 shares of the company’s stock after selling 12,200 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Tarsus Pharmaceuticals were worth $1,926,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Tarsus Pharmaceuticals by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock worth $449,000 after buying an additional 789 shares during the period. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $53,000. Franklin Resources Inc. grew its position in shares of Tarsus Pharmaceuticals by 9.3% in the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after purchasing an additional 1,033 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Tarsus Pharmaceuticals by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,282 shares of the company’s stock worth $905,000 after purchasing an additional 3,112 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after purchasing an additional 3,379 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Barclays lifted their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Finally, Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $56.00.

Tarsus Pharmaceuticals Stock Up 0.7 %

TARS opened at $54.50 on Wednesday. The stock’s 50 day simple moving average is $51.82 and its 200-day simple moving average is $40.31. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.14.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.